

Dr. Babita Kataria

MBBS, MD (General Medicine),

DM (Medical Oncology)

Designation: Assistant Professor, Medical
Oncology

Institute: National Cancer Institute-AIIMS, Jhajjar

Domain Expertise	Medical Oncology
Articles in Pub Med (Past 10 years)	07
H-index	04

Maximum of 10 primary research publications related to the proposal

Publication details in AMA style	Impact factor of journal	Name of policy/programme/ protocol document or patent/ commercialization of products where cited.
PD-9 Three-arm phase II/III randomized controlled trial in patients with unresectable/metastatic gall bladder cancer with poor performance status: Erlotinib or capecitabine v/s best supportive care. B Kataria , A Sharma, R Pramanik, R Sahoo, S Thulkar, M Yadav, S Mishra, et al. Annals of Oncology 33, S242	51.77	ESMO World GI Congress 2022, Barcelona, Spain.
Capecitabine+ best supportive care (BSC) or erlotinib+ BSC has overall survival (OS) benefit over BSC alone in unresectable/metastatic gall bladder cancer (GBC) patients with ECOG PS-III. Results from a phase II randomised controlled trial (RCT). B Kataria , A Sharma, S Mishra, S Bhatnagar, S Thulkar et al.- Annals of Oncology 30, v279	51.77	ESMO Congress 2019
High-dose chemotherapy followed by autologous stem cell transplant for multiple myeloma: Predictors of long-term outcome.L Kumar, D Ramavath, B Kataria , A Tiwari, A Raj, SK Chellapuram,et.al. The Indian journal of medical research 149 (6), 730	5.274	Autologous Stem cell transplant
Oral metronomic chemotherapy is a cost effective alternative to pazopanib in advanced soft tissue sarcoma. A Sharma, B Kataria , B Biswas, S Bakhshi, D Pushpam. Journal of Oncology Pharmacy Practice 28 (3), 560-568	1.416	Low-cost alternative anti-cancer treatment in LMICs
Pazopanib in rare histologies of metastatic soft tissue sarcoma. B Kataria , A Sharma, B Biswas, S Bakhshi, D Pushpam. ecancermedicalsecience 15	1.85	Rare cancer types
Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH). Mouna Bidaraguppe BM, akash kumar, Atul Batra, Vinod Sharma, Babita Kataria , Ajay Gogia, Sandeep Mathur, Aparna Sharma. Journal of Clinical Oncology 41 (16 suppl), TPS631-TPS631	45.3	Trials in Progress ASCO 2023 annual meeting
Olanzapine versus fosaprepitant for prevention of chemotherapy induced nausea and vomiting in patients receiving carboplatin (AUC \geq 4) containing chemotherapy regimen: A phase 3 randomized, double-blind, placebo-controlled	45.3	MASCC Annual congress 2022, Japan

trial.S Bhargave, A Kumar, V Sharma, B Kataria et.al. Journal of Clinical Oncology 40 (16_suppl), TPS12149-TPS12149		
Stop Imatinib: Real World Data from a Tertiary Care Center in India. B Kataria , A Upadhyay, L Kumar. Clinical Lymphoma, Myeloma and Leukemia 19, S301	2.7	Society of Hematologic Oncology Annual Meeting 2019, Houston, Texas.

List of projects undertaken since 01-01-2019:

Short title of project (Max. 10 words)	Role PI/Co-PI	Funding agency	Amount of funding	Reference of main publications
Phase II/III RCT to compare Erlotinib/Capecitabine with BSC only in Gall bladder cancer patients unfit for chemotherapy.	PI	AIIMS, Delhi	All investigations and treatments made free for trial patients	Presented at ESMO World Congress on GI cancer 2022, in pre-publication stage
Phase II RCT to test if olanzapine improves quality of life with palliative chemotherapy	PI	AIIMS, Delhi	All investigations and treatments made free for trial patients	Completed accrual and follow up on 15 Nov. 2023. Under data analysis stage
Phase II Non-randomised calibrated trial to test efficacy of consolidation chemotherapy in locally advanced cervical cancer	PI	AIIMS, Delhi	INR 5,00,000/-	Funding secured

List of patents since 01-01-2018: NA

Title of Patent	Date of filing	Name of the institute (collaborative)	Whether patent is commercialized or not, If yes, Give the details